Summary We demonstrate the expression of angiotensin 11 type 1 (AT1) receptors in normal and diseased human breast tissues. Using monoclonal antibody 6313/G2, directed against a specific sequence in the extracellular domain of the AT1 receptor, immunocytochemical analysis revealed positive immunoreactivity in membrane and cytoplasm of specific cell types. Immunoblotting of solubilized proteins separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) from benign and malignant tumours identified a single immunoreactive species with a molecular mass of approximately 60 kDa, consistent with that of the mature glycosylated receptor. In studies of [1251]angiotensin 11 binding using breast membrane preparations, concentrations of specific angiotensin 11 binding sites were found to range from 1.8 to 100 fmol mg-' protein, with a Kd of approximately 60 nm. Most of the specifically bound [1251]angiotensin II was displaced by losartan, a specific angiotensin 11 type 1 receptor antagonist, while less was displaced by the AT2 receptor type antagonist, CGP42112A, thus confirming the prevalence of AT1 receptors in this tissue type. These data suggest that the renin-angiotensin system may be involved in normal and abnormal breast tissue function.
Angiotensin II plays a central role in mammalian electrolyte homeostasis and blood pressure control (Peach, 1977; Vinson et al, 1992) . Two main subtypes of angiotensin II receptors, designated types 1 and 2 (ATl and AT2), have been recognized, but the majority of the well-known actions of angiotensin II occur via the ATI subtype (Herblin et al, 1991; Ouali et al, 1992) . Local tissue renin-angiotensin systems have been demonstrated in several tissues, and in some cases it has been suggested that local production of angiotensin II may be particularly concerned in trophic actions (Vinson et al, 1995a) .
The availability of our recently developed monoclonal antibody (6313/G2) to the ATI receptor subtype (Barker et al, 1993a) has facilitated the further study of its distribution (Vinson et al, 1995a) . We describe here studies investigating the presence of the ATl receptor in normal and diseased breast.
MATERIAL AND METHODS
Fresh breast tissue samples were obtained with appropriate informed consent from 22 patients undergoing breast surgery. Samples obtained for the study were selected by the pathologist responsible for handling the specimen, divided and the larger portion immediately snap frozen in liquid nitrogen for future immunocytochemical and biochemical assay. The remainder was fixed in 10% formalin-saline for 24 h before paraffin wax embedding.
Received 16 May 1996 Accepted 11 November 1996 Correspondence to: GP Vinson Staining procedure Breast tissue sections (4 im) were dewaxed in xylene and dehydrated in alcohol at room temperature. Human adrenal gland sections were used as positive controls.
Sections were then immersed in endogenous peroxidase blocking solution (3 ml of 100 volume hydrogen peroxide and 97 ml of methanol; 15 min), washed in tap water (10 min) and distilled water (5 min). Sections were immersed in 10 mm citrate buffer, pH 6.0, covered loosely with 'Saranwrap' (Dow Chemical Co.) and boiled in a microwave oven for 10 min at 630 w (H2500 BioRad, Watford, Herts., UK). After standing for 10 min in hot buffer, sections were washed in tap water (5 min) and transferred to 0.05 M Tris-buffered saline, pH 7.6 (TBS).
Tissue sections were then incubated with normal rabbit serum (Dako, High Wycombe, Bucks., UK) diluted 1:5 in Tris-buffered saline (20 min) and incubated (60 min) with mouse primary antibody 6313/G2 (Barker et al, 1993a) (BDH). Negative control sections were treated similarly except that culture medium containing non-specific mouse IgG was substituted for primary antibody. The sections were viewed under a Leitz Laborlux microscope.
Membrane preparation
Tissues were retrieved from liquid nitrogen, and samples of approximately g wet weight were homogenized in a homogenizer (Polytron, Kinematica AG, Switzerland) in ice-cold 50 mm Tris-HCl buffer, pH 7.4, containing 1 gg ml-1 each of protease inhibitors aprotinin and soybean trypsin inhibitor and 30 jig ml-1 phenylmethylsulphonyl fluoride (Sigma) at 4'C. Homogenates were centrifuged at 800 g for 10 min at 4°C. The supernatant was recentrifuged at 100 000 g for 1 h and the resultant pellet resuspended in Tris-HCl containing protease inhibitors, 100 mm sodium chloride, 6 mm magnesium chloride (THP) and % bovine serum albumin (BSA) and used immediately or stored at -70°C until used. (Figure 3 ).
Immunoblotting
Using solubilized membranes from human benign and malignant breast tumours, immunoblotting studies after SDS-PAGE fractionation revealed a single immunoreactive band with a molecular mass of approximately 60 kDa (Figure 4 ).
DISCUSSION
The development of an antibody to the angiotensin II type receptor has enabled us to extend our knowledge of the receptor's distribution. The antibody is highly specific: it identifies the British Journal of Cancer (1997) receptor in COS-7 cells that have been transfected with the gene coding for the receptor, but not in untransfected cells (Barker et al, 1993a,b) , and it also identifies the receptor accurately in a variety of tissues, including the adrenal cortex, the vasculature and in epithelial tissues that have been shown to be angiotensin II responsive by other means, including ligand binding and functional assays (Vinson et al, 1995a,b; Saridogan et al, 1996a,b) . Taken together, the data presented here clearly demonstrate the presence of angiotensin II type 1 receptors in both normal and diseased human breast tissue. The data are consistent with our findings in other tissue types (Vinson et al, 1995a ) that the receptor is present in epithelial (and endothelial) cells and may be localized on the membrane or in cytoplasmic sites (Figure 1) . It is known from other studies that the receptor may be intemalized within the cell and recycled to the cell surface, and that its cellular distribution thus depends on the extent of receptor occupancy by the hormone (Ullian and Linas, 1989) . Scatchard analysis confirms the presence of receptor-like specific angiotensin II binding sites, and the use of the subtype-specific antagonists, losartan and CGP42112A, confirms that most of these sites are indeed ATI receptors (Figures 2 and 3) . The possibility of a biphasic Scatchard plot for the normal tissue cannot be excluded (see Figure 2a ), but it should be remembered that these reflect both the ATI and AT2 receptor-binding capacities (cf. Figure 3) . Both the kd of the receptor and its molecular mass, as determined by immunoblotting (Figure 4 ), are consistent with findings for the ATI receptor in other tissues (Barker et al, 1993a,b; Desamaud et al, 1993) .
It is of particular interest that both normal breast tissue and tumours express the receptor in epithelial cells of both ducts and lobules, suggesting a role for this hormone in the maintenance of tissue structure and function. Indeed, recent work now proposes a role of angiotensin II as a tissue or paracrine hormone (Vinson et al, 1995a) , and our own studies on the distribution of the ATI receptor confirm this. In brief, several localized tissue reninangiotensin systems have been described, particularly in the adrenal gland, uterus (Capponi and Catt, 1980) , heart (Okura et al, 1992) , pituitary and brain (Mendelson et al, 1984; Trolliet and Phillips, 1992) . In the present context, it is therefore pertinent that significant levels of angiotensin-converting enzyme activity have been measured in human breast tissue (Dzau, 1993) . The existence of local RAS systems in addition to the systemic RAS suggests that the generation of angiotensin II in close proximity to its receptors may be important in ensuring that tissue-specific functions are precisely regulated, without concomitant inappropriate actions in unrelated tissues.
From comparison with other tissues, it is possible that the expression of angiotensin receptors in breast tissue may reflect a role in cell growth and/or development (Vinson et al, 1992 (Vinson et al, , 1995a Varela and Saez, 1993) . Given the complexity of the local and systemic RAS mechanisms, it is also conceivable that these functions may be perturbed in disease. For example, it has been shown that converting enzyme inhibitors and peptide angiotensin II antagonists are capable of reducing the growth of neuroblastoma cells in culture (Chen et al, 1993) and also that angiotensin receptors are down-regulated in hepatic tumours, causing selective arterial vasoconstriction in surrounding normal liver (Sitzman et al, 1994) . A similar observation has been made in breast cancer patients (Noguchi et al, 1988) and is already being exploited in regional intra-arterial infusions of chemotherapeutic agents. From the examples we give here, it is obvious that malfunction of tissue RAS could give rise to any of a spectrum of quite unrelated problems. In view of the widespread incidence of the ATI receptor in epithelial tissue, and the potential for involvement of the tissue RAS in growth-promoting and tissue-modelling events, one further striking possibility is that the presence of angiotensin receptors in malignant breast epithelial cells raises the prospect that All may be involved in the development of cancer.
